280 results
This study has been transitioned to CTIS with ID 2024-518046-25-00 check the CTIS register for the current data. Evaluation of the feasibility of intraoperative visualization of penile and tongue tumours using the fluorescent tracer EMI-137.
The primary objectives of this trial are:- To determine the safety and tolerability of increasing doses of PRECIOUS-01 after intravenous (i.v.) administration in subjects with solid tumors;- To assess the effect of increasing doses of PRECIOUS-01 on…
(1) To evaluate the (cost-)effectiveness of an individual rehabilitation program on RTW and continuation of work in cancer patients with an employment contract, compared to care as usual (CAU). In addition, we will investigate the effect of the…
This study has been transitioned to CTIS with ID 2024-513033-21-00 check the CTIS register for the current data. Primary:• To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified…
Cohorts A nd B :The primary objective is to evaluate the objective response rate (ORR) in patients with solid tumors harboring FGFRrearrangements or gastric cancer (including GEJ cancer) harboring FGFR2 amplifications based on independent central…
This study has been transitioned to CTIS with ID 2023-509881-39-00 check the CTIS register for the current data. The aim of this study is to evaluate the difference in the fraction of patients that have disease progression within 6 months after…
Primary: To characterize safety and tolerability of LTT462 and identify a recommended dose and regimen for future studies in adult patients with advanced solid tumors harboring MAPK pathway alterations. Secondary: Preliminary anti-tumor activity,…
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
Phase 1 Dose Escalation:Phase 1 Dose Escalation has been completed as of Amendment 6Phase 1 Expansion Primary• To evaluate ORR in cholangiocarcinoma (intra-hepatic [iCCA] or extra-hepatic [eCCA]) patients with tumors harboring FGFR2 gene fusions or…
This study has been transitioned to CTIS with ID 2024-514791-40-00 check the CTIS register for the current data. Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed…
Primary objective is to determine the gland-based dose-effect relation between conventionally fractionated radiotherapy (RT) and long-term loss of acinar cells, per salivary gland type. Secondary objectives are:- To estimate the dose-effect relation…
To establish the negative predictive value of the designed KIT exon 11 circulating tumor mutation assay in relation to CT-scans (and/or MRI scans).
Primary objectives: • To define any alterations in the oral and gut microbiome and metabolome in patients with HNSCC compared to healthy controls;• To investigate the dynamics oral and gut microbiome and metabolome in HNSCC before, during and after…
Objectives (all are exploratory):• To measure and analyze 89Zr-Df-IAB22M2C uptake cluster of (CD8+ PET signal) at and between baseline and post-treatment in tumor lesions and reference normal tissues, including T-cell rich tissues, using PET imaging…
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study (MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and Functional MRGRT and facilitate the evidence-based introduction of the MR-Linac into…
To evaluate the safety and clinical utility of PEF treatment of advanced stage or metastatic cancer following progression on immunotherapy
Primary Objective:To assess the safety and tolerability and determine the MTD and the RP2D of CB307 in patients with PSMA+ tumoursSecondary Objectives:• To characterise the serum PK of CB307• To characterise the immunogenic potential of CB307 and…
Primary Objective: to explore the effect of SMIs on the pharmacokinetics of DOACs in patients with solid tumours who receive a DOAC and SMI concurrently. Secondary Objective(s): - To determine the percentage of patients with DOAC peak and trough…
This study has been transitioned to CTIS with ID 2023-505067-36-00 check the CTIS register for the current data. Primary objective: To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484…
Primary ObjectivesPart 1 (Monotherapy Dose Escalation Phase):* To determine the recommended Phase 2 dose (RP2D) of SQZ AAC HPV monotherapy. * To characterize the safety and tolerability of SQZ AAC HPV administered as monotherapy. Part 2 (Combination…